Scholar Rock Holding Corporation's Stock Performance and Analyst Ratings

Core Viewpoint - Scholar Rock Holding Corporation (SRRK) is a biopharmaceutical company focused on innovative treatments for serious diseases, currently receiving a consensus recommendation of "Buy" from analysts [1] Analyst Recommendations - Sixteen brokerages have provided recommendations for SRRK, including one sell, eleven buy, and four strong buy ratings [1] - Michael Yee from UBS has set a price target of $60 for SRRK, indicating a potential increase of approximately 45.24% from its current price of $41.31 [2][5] - The average 12-month price target among analysts is $48.9, with Barclays raising its target from $45 to $52 while maintaining an "overweight" rating [2][5] - Cantor Fitzgerald reiterated an "overweight" rating on December 11, while Wolfe Research began coverage with an "outperform" rating and a price target of $42 [3] Stock Performance - The stock has experienced fluctuations, with a recent low of $41.19 and a high of $43.06 [4] - Over the past year, SRRK has reached a high of $48.28 and a low of $22.71 [4] - The company's market capitalization is approximately $4.21 billion, with a trading volume of 707,076 shares, indicating active investor interest [4]